Trial Profile
A Phase IIb/III Randomized Multicenter Active Control to evaluate Efficacy and Safety of topical application of recombinant Lysostaphin (150µg/g) gel formulation in subjects with uncomplicated Staphylococcus aureus and Methicillin resistant Staphylococcus aureus skin and skin structure infections.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Lysostaphin (Primary) ; Mupirocin
- Indications Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
- Focus Therapeutic Use
- Sponsors Bharat Biotech
- 30 Apr 2018 Status changed from recruiting to completed.
- 13 Dec 2016 New trial record